Similar Articles
691 Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation
692 Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
693 Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma
694 Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma
695 Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
696 One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation
697 Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives
698 Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future
699 Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm
700 Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA